CDK4 and breast cancer: Different randomized trials have shown that the addition of CDK4/6i to conventional hormone therapy can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients with advanced HR+/HER2− BC [12,13,14,15,16,17,18,19,20].